Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bendamustine||Treanda||Ribomustin|SyB L-0501|SDX-105||Chemotherapy - Alkylating 16||Treanda (bendamustine) is an alkylating agent with unique mechanisms, resulting in increased DNA damage and base-excision DNA repair pathway induction, and potentially leading to decreased growth of tumors, including those resistant to other alkylating agents (PMID: 18172283, PMID: 19117340, PMID: 19224851). Treanda (bendamustine) is FDA approved for use in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma (FDA.gov).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|iC9-CAR.19-IL15-Transduced CB-NK||iC9/CAR.19/IL15-Transduced CB-NK cells are cord blood-derived natural killer cells that have modified to express a chimeric antigen receptor directed to CD19, as well as IL-15 and inducible caspase-9, which may result in increased death of CD19-expressing tumor cells (PMID: 28725044).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03696784||Phase I||Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK||Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma||Recruiting||USA||0|